Can-Fite Submits Phase 2 Study Protocol
Can-Fite submits phase 2 study for piclidenoson
Story updates
12:14:26 PM UTC
SquawkNews
CANF some vol pm CANF Can-Fite BioPharma Submitted Phase 2 protocol to test Piclidenoson in Lowe syndrome, a rare genetic disease with no approved therapies — Study run at Bambino Gesù Children's Hospital in Rome — Small trial: 5 adult patients, six months of oral dosing — Partnered with Fondazione Telethon on the program
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.